

TEST CHANGE

Oxcarbazepine or Eslicarbazepine Metabolite (MHD)

0098834, OXCARB

Specimen Requirements:

Patient Preparation: Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.

Collect: Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2 EDTA).

Specimen Preparation: Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).

Remarks:

Stability: After separation from cells: Ambient: 6 weeks; Refrigerated: 6 weeks; Frozen: 3 months (avoid repeated freeze/thaw cycles)

Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Performed: Sun-Sat

Reported: 1-53 days

Note:

CPT Codes: 80183

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

This test measures monohydroxyoxcarbazepine (MHD). Adverse effects may include dizziness, fatigue, nausea, headache, somnolence, ataxia and tremor.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Effective November 18, 2013

Therapeutic Range:	3-35 ug/mL	
Toxic:	Greater than 40 ug/mL	